Login Register Cart 0
Generic placeholder image

Recent Patents on Inflammation & Allergy Drug Discovery

Editor-in-Chief

ISSN (Print): 1872-213X
ISSN (Online): 2212-2710

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Onychomycosis: An Updated Review

Author(s): Alexander K.C. Leung*, Joseph M. Lam, Kin F. Leong, Kam L. Hon, Benjamin Barankin, Amy A.M. Leung and Alex H.C. Wong

Volume 14, Issue 1, 2020

Page: [32 - 45] Pages: 14

DOI: 10.2174/1872213X13666191026090713

Abstract

Background: Onychomycosis is a common fungal infection of the nail.

Objective: The study aimed to provide an update on the evaluation, diagnosis, and treatment of onychomycosis.

Methods: A PubMed search was completed in Clinical Queries using the key term “onychomycosis”. The search was conducted in May 2019. The search strategy included meta-analyses, randomized controlled trials, clinical trials, observational studies, and reviews published within the past 20 years. The search was restricted to English literature. Patents were searched using the key term “onychomycosis” in www.freepatentsonline.com.

Results: Onychomycosis is a fungal infection of the nail unit. Approximately 90% of toenail and 75% of fingernail onychomycosis are caused by dermatophytes, notably Trichophyton mentagrophytes and Trichophyton rubrum. Clinical manifestations include discoloration of the nail, subungual hyperkeratosis, onycholysis, and onychauxis. The diagnosis can be confirmed by direct microscopic examination with a potassium hydroxide wet-mount preparation, histopathologic examination of the trimmed affected nail plate with a periodic-acid-Schiff stain, fungal culture, or polymerase chain reaction assays. Laboratory confirmation of onychomycosis before beginning a treatment regimen should be considered. Currently, oral terbinafine is the treatment of choice, followed by oral itraconazole. In general, topical monotherapy can be considered for mild to moderate onychomycosis and is a therapeutic option when oral antifungal agents are contraindicated or cannot be tolerated. Recent patents related to the management of onychomycosis are also discussed.

Conclusion: Oral antifungal therapies are effective, but significant adverse effects limit their use. Although topical antifungal therapies have minimal adverse events, they are less effective than oral antifungal therapies, due to poor nail penetration. Therefore, there is a need for exploring more effective and/or alternative treatment modalities for the treatment of onychomycosis which are safer and more effective.

Keywords: Dermatophytes, itraconazole, nail discoloration, onychauxis, onycholysis, subungual hyperkeratosis, terbinafine.

« Previous Next »
[1]
Hoy NY, Leung AK, Metelitsa AI, Adams S. New concepts in median nail dystrophy, onychomycosis, and hand, foot, and mouth disease nail pathology. ISRN Dermatol 2012; 2012 680163
[http://dx.doi.org/10.5402/2012/680163] [PMID: 22462009 ]
[2]
Vlahovic TC. Onychomycosis: Evaluation, treatment options, managing recurrence, and patient outcomes. Clin Podiatr Med Surg 2016; 33(3): 305-18.
[http://dx.doi.org/10.1016/j.cpm.2016.02.001] [PMID: 27215153]
[3]
Queller JN, Bhatia N. The dermatologist’s approach to onychomycosis. J Fungi (Basel) 2015; 1(2): 173-84.
[http://dx.doi.org/10.3390/jof1020173] [PMID: 29376907]
[4]
Thomas J, Peterson GM, Christenson JK, Kosari S, Baby KE. Antifungal drug use for onychomycosis. Am J Ther 2019; 26(3): e388-96.
[http://dx.doi.org/10.1097/MJT.0000000000000696] [PMID: 31082864 ]
[5]
Gupta AK, Versteeg SG, Shear NH. Confirmatory testing prior to initiating onychomycosis therapy is cost-effective. J Cutan Med Surg 2018; 22(2): 129-41.
[http://dx.doi.org/10.1177/1203475417733461] [PMID: 28954534 ]
[6]
Gupta AK, Mays RR, Versteeg SG, Shear NH, Piguet V. Update on current approaches to diagnosis and treatment of onychomycosis. Expert Rev Anti Infect Ther 2018; 16(12): 929-38.
[http://dx.doi.org/10.1080/14787210.2018.1544891] [PMID: 30411650]
[7]
Angelo T, Borgheti-Cardoso LN, Gelfuso GM, Taveira SF, Gratieri T. Chemical and physical strategies in onychomycosis topical treatment: A review. Med Mycol 2017; 55(5): 461-75.
[PMID: 27703019]
[8]
Bodman MA, Krishnamurthy K. Onychomycosis. StatPearls [Internet]. aTreasure Island (FL): StatPearls Publishing; 2019 Jan- 2019 Jan 5.
[9]
Gupta AK, Sibbald RG, Andriessen A, Belley R, Boroditsky A, Botros M, et al. Toenail onychomycosis - A Canadian approach with a new transungual treatment: Development of a clinical pathway. J Cutan Med Surg 2015; 19(5): 440-9.
[http://dx.doi.org/10.1177/1203475415581310] [PMID: 25857439]
[10]
Joyce A, Gupta AK, Koenig L, Wolcott R, Carviel J. Fungal diversity and onychomycosis: An analysis of 8,816 toenail samples using quantitative PCR and next-generation sequencing. J Am Podiatr Med Assoc 2019; 109(1): 57-63.
[http://dx.doi.org/10.7547/17-070] [PMID: 30964314 ]
[11]
Thomas J, Jacobson GA, Narkowicz CK, Peterson GM, Burnet H, Sharpe C. Toenail onychomycosis: An important global disease burden. J Clin Pharm Ther 2010; 35(5): 497-519.
[http://dx.doi.org/10.1111/j.1365-2710.2009.01107.x] [PMID: 20831675]
[12]
Youssef AB, Kallel A, Azaiz Z, Jemel S, Bada N, Chouchen A, et al. Onychomycosis: Which fungal species are involved? Experience of the Laboratory of Parasitology-Mycology of the Rabta Hospital of Tunis. J Mycol Med 2018; 28(4): 651-4.
[http://dx.doi.org/10.1016/j.mycmed.2018.07.005] [PMID: 30107987 ]
[13]
Fike JM, Kollipara R, Alkul S, Stetson CL. Case report of onychomycosis and tinea corporis due to Microsporum gypseum. J Cutan Med Surg 2018; 22(1): 94-6.
[http://dx.doi.org/10.1177/1203475417724439] [PMID: 28817957 ]
[14]
Lipner SR, Scher RK. Onychomycosis: Clinical overview and diagnosis. J Am Acad Dermatol 2019; 80(4): 835-51.
[http://dx.doi.org/10.1016/j.jaad.2018.03.062] [PMID: 29959961 ]
[15]
Pang SM, Pang JYY, Fook-Chong S, Tan AL. Tinea unguium onychomycosis caused by dermatophytes: A ten-year (2005-2014) retrospective study in a tertiary hospital in Singapore. Singapore Med J 2018; 59(10): 524-7.
[http://dx.doi.org/10.11622/smedj.2018037] [PMID: 29552686]
[16]
Sato T, Kitahara H, Honda H, Katsukawa F, Hiruma M, Yaguchi T. Onychomycosis of the middle finger of a Japanese judo athlete due to Trichophyton tonsurans. Med Mycol J 2019; 60(1): 1-4.
[http://dx.doi.org/10.3314/mmj.18-00012] [PMID: 30814464 ]
[17]
Solís-Arias MP, García-Romero MT. Onychomycosis in children. A review. Int J Dermatol 2017; 56(2): 123-30.
[http://dx.doi.org/10.1111/ijd.13392] [PMID: 27612431]
[18]
Bombace F, Iovene MR, Galdiero M, Martora F, Nicoletti GF, D’Andrea M, et al. Non-dermatophytic onychomycosis diagnostic criteria: an unresolved question. Mycoses 2016; 59(9): 558-65.
[http://dx.doi.org/10.1111/myc.12504] [PMID: 27061613 ]
[19]
Bongomin F, Batac CR, Richardson MD, Denning DW. A review of onychomycosis due to Aspergillus species. Mycopathologia 2018; 183(3): 485-93.
[http://dx.doi.org/10.1007/s11046-017-0222-9] [PMID: 29147866]
[20]
Hirose M, Noguchi H, Yaguchi T, Matsumoto T, Hiruma M, Fukushima S, et al. Onychomycosis caused by Aspergillus subramanianii. J Dermatol 2018; 45(11): 1362-6.
[http://dx.doi.org/10.1111/1346-8138.14616] [PMID: 30144137 ]
[21]
Hon KL, Leung AK. Alopecia areata. Recent Pat Inflamm Allergy Drug Discov 2011; 5(2): 98-107.
[http://dx.doi.org/10.2174/187221311795399291] [PMID: 21453266]
[22]
Kimura U, Hiruma M, Kano R, Matsumoto T, Takamori K, Suga Y. Onychomycosis caused by Scopulariopsis brevicaulis: The third documented case in Japan. J Dermatol 2019; 46(5): e167-8.
[http://dx.doi.org/10.1111/1346-8138.14677] [PMID: 30303252 ]
[23]
Martínez-Herrera EO, Arroyo-Camarena S, Tejada-García DL, Porras-López CF, Arenas R. Onychomycosis due to opportunistic molds. An Bras Dermatol 2015; 90(3): 334-7.
[http://dx.doi.org/10.1590/abd1806-4841.20153521] [PMID: 26131862 ]
[24]
Matsuyama Y, Nakamura T, Hagi T, Asanuma K, Sudo A. Subungual onychomycosis due to Aspergillus niger mimicking a glomus tumor: A case report. Biomed Rep 2017; 7(6): 532-4.
[http://dx.doi.org/10.3892/br.2017.994] [PMID: 29188057 ]
[25]
Mohanty P, Dash S, Mohapatra L, Jain M. Total dystrophic onychomycosis due to Syncephalastrum racemosum - A rare cause and its novel treatment option. Indian Dermatol Online J 2019; 10(2): 171-3.
[PMID: 30984595]
[26]
Moreno G, Arenas R. Other fungi causing onychomycosis. Clin Dermatol 2010; 28(2): 160-3.
[http://dx.doi.org/10.1016/j.clindermatol.2009.12.009] [PMID: 20347658 ]
[27]
Noguchi H, Hiruma M, Miyashita A, Makino K, Miyata K, Ihn H. A case of fingernail onychomycosis due to Aspergillus flavus. Med Mycol J 2016; 57(2): E21-5.
[http://dx.doi.org/10.3314/mmj.57.E21] [PMID: 27251317 ]
[28]
Piraccini BM, Alessandrini A. Onychomycosis: A review. J Fungi (Basel) 2015; 1(1): 30-43.
[http://dx.doi.org/10.3390/jof1010030] [PMID: 29376897 ]
[29]
Pontini P, Gorani A, Veraldi S. Onychomycosis by Paecilomyces lilacinus. G Ital Dermatol Venereol 2016; 151(6): 706-9.
[PMID: 27824223]
[30]
Pote ST, Khan U, Lahiri KK, Patole MS, Thakar MR, Shah SR. Onychomycosis due to Achaetomium strumarium. J Mycol Med 2018; 28(3): 510-3.
[http://dx.doi.org/10.1016/j.mycmed.2018.07.002] [PMID: 30104134 ]
[31]
Veiga FF, de Castro-Hoshino LV, Sato F, Bombassaro A, Vicente VA, Mendes V, et al. Fusarium oxysporum is an onychomycosis etiopathogenic agent. Future Microbiol 2018; 13: 1745-56.
[http://dx.doi.org/10.2217/fmb-2018-0245] [PMID: 30507250]
[32]
Welsh O, Vera-Cabrera L, Welsh E. Onychomycosis. Clin Dermatol 2010; 28(2): 151-9.
[http://dx.doi.org/10.1016/j.clindermatol.2009.12.006] [PMID: 20347657]
[33]
Subramanya SH, Subedi S, Metok Y, Kumar A, Prakash PY, Nayak N. Distal and lateral subungual onychomycosis of the finger nail in a neonate: A rare case. BMC Pediatr 2019; 19(1): 168.
[http://dx.doi.org/10.1186/s12887-019-1549-9] [PMID: 31133007 ]
[34]
Ge G, Yang Z, Li D, Sybren de Hoog G, Shi D. Onychomycosis with greenish-black discolorations and recurrent onycholysis caused by Candida parapsilosis. Med Mycol Case Rep 2019; 24: 48-50.
[http://dx.doi.org/10.1016/j.mmcr.2019.04.005] [PMID: 31024790 ]
[35]
Seebacher C, Brasch J, Abeck D, Cornely O, Effendy I, Ginter-Hanselmayer G, et al. Onychomycosis. J Dtsch Dermatol Ges 2007; 5(1): 61-6.
[http://dx.doi.org/10.1111/j.1610-0387.2007.06134.x] [PMID: 17229207]
[36]
Goldstein AO, Bhatia N. Onychomycosis: Epidemiology, clinical features, and diagnosis. In: Post TW, edUp To Date. Waltham, MA. (Accessed on June 30, 2019).
[37]
Zane LT, Chanda S, Coronado D, Del Rosso J. Antifungal agents for onychomycosis: New treatment strategies to improve safety. Dermatol Online J 2016; 22(3): 1.
[PMID: 27136621]
[38]
Sigurgeirsson B, Baran R. The prevalence of onychomycosis in the global population: A literature study. J Eur Acad Dermatol Venereol 2014; 28(11): 1480-91.
[http://dx.doi.org/10.1111/jdv.12323] [PMID: 24283696]
[39]
Christenson JK, Peterson GM, Naunton M, Bushell M, Kosari S, Baby KE, et al. Challenges and opportunities in the management of onychomycosis. J Fungi (Basel) 2018; 4(3)pii: E87
[http://dx.doi.org/10.3390/jof4030087] [PMID: 30042327]
[40]
Gupta AK, Cernea M, Foley KA. Improving cure rates in onychomycosis. J Cutan Med Surg 2016; 20(6): 517-31.
[http://dx.doi.org/10.1177/1203475416653734] [PMID: 27313230 ]
[41]
Ghannoum MA, Hajjeh RA, Scher R, Konnikov N, Gupta AK, Summerbell R, et al. A large-scale North American study of fungal isolates from nails: The frequency of onychomycosis, fungal distribution, and antifungal susceptibility patterns. J Am Acad Dermatol 2000; 43(4): 641-8.
[http://dx.doi.org/10.1067/mjd.2000.107754] [PMID: 11004620 ]
[42]
Cozzani E, Agnoletti AF, Speziari S, Schiavetti I, Zotti M, Persi A, et al. Epidemiological study of onychomycosis in older adults with onychodystrophy. Geriatr Gerontol Int 2016; 16(4): 486-91.
[http://dx.doi.org/10.1111/ggi.12496] [PMID: 25981058 ]
[43]
Gupta AK, Studholme C. Update on efinaconazole 10% topical solution for the treatment of onychomycosis. Skin Therapy Lett 2016; 21(6): 7-11.
[PMID: 27825175]
[44]
Rosen T, Friedlander SF, Kircik L, Zirwas MJ, Stein Gold L, Bhatia N, et al. Onychomycosis: Epidemiology, diagnosis, and treatment in a changing landscape. J Drugs Dermatol 2015; 14(3): 223-33.
[PMID: 25738843]
[45]
Rosen T. Tinea and onychomycosis. Semin Cutan Med Surg 2016; 35(Suppl. 6): S110-3.
[http://dx.doi.org/10.12788/j.sder.2016.035] [PMID: 27537822]
[46]
Allevato MA. Diseases mimicking onychomycosis. Clin Dermatol 2010; 28(2): 164-77.
[http://dx.doi.org/10.1016/j.clindermatol.2009.12.001] [PMID: 20347659 ]
[47]
Assadamongkol R, Lertwattanarak R, Wannachalee T, Bunyaratavej S, Leeyaphan C, Matthapan L. Prevalence, risk factors, and type of organism in fungal foot infection and toenail onychomycosis in Thai diabetic patients. J Med Assoc Thai 2016; 99(6): 659-64.
[PMID: 29900728]
[48]
Cathcart S, Cantrell W, Elewski Be. Onychomycosis and diabetes. J Eur Acad Dermatol Venereol 2009; 23(10): 1119-22.
[http://dx.doi.org/10.1111/j.1468-3083.2009.03225.x] [PMID: 19309423]
[49]
Daggett C, Brodell RT, Daniel CR, Jackson J. Onychomycosis in athletes. Am J Clin Dermatol 2019; 20(5): 691-8.
[http://dx.doi.org/10.1007/s40257-019-00448-4] [PMID: 31111408]
[50]
Gallo L, Cinelli E, Fabbrocini G, Vastarella M. A 15-year retrospective study on the prevalence of onychomycosis in psoriatic vs non-psoriatic patients: A new European shift from dermatophytes towards yeast. Mycoses 2019; 62(8): 659-64.
[http://dx.doi.org/10.1111/myc.12925] [PMID: 31062415]
[51]
Gómez-Moyano E, Crespo-Erchiga V. HIV infection manifesting as proximal white onychomycosis. N Engl J Med 2017; 377(18) e26
[http://dx.doi.org/10.1056/NEJMicm1703082] [PMID: 29091566]
[52]
Jimenez-Gonzalez C, Mata-Marin JA, Arroyo-Anduiza CI, Ascencio-Montiel Ide J, Fuentes-Allen JL, Gaytan-Martinez J. Prevalence and etiology of onychomycosis in the HIV-infected Mexican population. Eur J Dermatol 2013; 23(3): 378-81.
[http://dx.doi.org/10.1684/ejd.2013.2015] [PMID: 23816463 ]
[53]
Lipner SR, Scher RK. Onychomycosis: Treatment and prevention of recurrence. J Am Acad Dermatol 2019; 80(4): 853-67.
[http://dx.doi.org/10.1016/j.jaad.2018.05.1260] [PMID: 29959962 ]
[54]
Papini M, Piraccini BM, Difonzo E, Brunoro A. Epidemiology of onychomycosis in Italy: Prevalence data and risk factor identification. Mycoses 2015; 58(11): 659-64.
[http://dx.doi.org/10.1111/myc.12396] [PMID: 26412300]
[55]
Shemer A, Gupta AK, Amichai B, Baum S, Barzilai A, Farhi R, et al. Increased risk of tinea pedis and onychomycosis among swimming pool employees in Netanya area, Israel. Mycopathologia 2016; 181(11-12): 851-6.
[http://dx.doi.org/10.1007/s11046-016-0040-5] [PMID: 27435974 ]
[56]
Tabassum S, Rahman A, Awan S, Jabeen K, Farooqi J, Ahmed B, et al. Factors associated with onychomycosis in nail psoriasis: A multicenter study in Pakistan. Int J Dermatol 2019; 58(6): 672-8.
[http://dx.doi.org/10.1111/ijd.14364] [PMID: 30615189 ]
[57]
Grover C, Khurana A. Onychomycosis: Newer insights in pathogenesis and diagnosis. Indian J Dermatol Venereol Leprol 2012; 78(3): 263-70.
[http://dx.doi.org/10.4103/0378-6323.95440] [PMID: 22565425 ]
[58]
Gupta AK, Foley KA. Evidence for biofilms in onychomycosis. G Ital Dermatol Venereol 2019; 154(1): 50-5.
[http://dx.doi.org/10.23736/S0392-0488.18.06001-7] [PMID: 29683287 ]
[59]
Monteagudo B, Figueroa O, Suárez-Magdalena O, Méndez-Lage S. Green nail caused by onychomycosis coinfected with Pseudomonas aeruginosa. Actas Dermosifiliogr 2019; 110(9): 783-5.
[http://dx.doi.org/10.1016/j.adengl.2018.04.023] [PMID: 31010574 ]
[60]
Akhtar N, Sharma H, Pathak K. Onychomycosis: Potential of nail lacquers in transungual delivery of antifungals. Scientifica (Cairo) 2016; 2016 1387936
[http://dx.doi.org/10.1155/2016/1387936] [PMID: 27123362 ]
[61]
Gupta AK, Mays RR, Versteeg SG, Piraccini BM, Takwale A, Shemer A, et al. Global perspectives for the management of onychomycosis. Int J Dermatol 2019; 58(10): 1118-29.
[http://dx.doi.org/10.1111/ijd.14346] [PMID: 30585300 ]
[62]
Loo DS. Onychomycosis in the elderly: Drug treatment options. Drugs Aging 2007; 24(4): 293-302.
[http://dx.doi.org/10.2165/00002512-200724040-00003] [PMID: 17432924]
[63]
Shemer A. Update: Medical treatment of onychomycosis. Dermatol Ther 2012; 25(6): 582-93.
[http://dx.doi.org/10.1111/j.1529-8019.2012.01551.x] [PMID: 23210757 ]
[64]
Westerberg DP, Voyack MJ. Onychomycosis: Current trends in diagnosis and treatment. Am Fam Physician 2013; 88(11): 762-70.
[PMID: 24364524]
[65]
Baran R, Hay R, Perrin C. Superficial white onychomycosis revisited. J Eur Acad Dermatol Venereol 2004; 18(5): 569-71.
[http://dx.doi.org/10.1111/j.1468-3083.2004.01015.x] [PMID: 15324395]
[66]
Gupta AK, Versteeg SG, Shear NH. Confirmatory testing prior to treating toenail onychomycosis is recommended in Canada. J Cutan Med Surg 2018; 22(2): 244-5.
[http://dx.doi.org/10.1177/1203475417746126] [PMID: 29995444 ]
[67]
Scher RK, Tavakkol A, Sigurgeirsson B, Hay RJ, Joseph WS, Tosti A, et al. Onychomycosis: Diagnosis and definition of cure. J Am Acad Dermatol 2007; 56(6): 939-44.
[http://dx.doi.org/10.1016/j.jaad.2006.12.019] [PMID: 17307276 ]
[68]
Li DG, Cohen JM, Mikailov A, Williams RF, Laga AC, Mostaghimi A. Clinical diagnostic accuracy of onychomycosis: A multispecialty comparison study. Dermatol Res Pract 2018; 2018 2630176
[http://dx.doi.org/10.1155/2018/2630176] [PMID: 30057595]
[69]
Yorulmaz A, Yalcin B. Dermoscopy as a first step in the diagnosis of onychomycosis. Postepy Dermatol Alergol 2018; 35(3): 251-8.
[http://dx.doi.org/10.5114/ada.2018.76220] [PMID: 30008642 ]
[70]
Nirmal B. Utility of a multispectral dermatoscope in onychomycosis. Indian J Dermatol 2018; 63(1): 87-8.
[http://dx.doi.org/10.4103/ijd.IJD_37_17] [PMID: 29527038]
[71]
Piraccini BM, Balestri R, Starace M, Rech G. Nail digital dermoscopy (onychoscopy) in the diagnosis of onychomycosis. J Eur Acad Dermatol Venereol 2013; 27(4): 509-13.
[http://dx.doi.org/10.1111/j.1468-3083.2011.04323.x] [PMID: 22040510]
[72]
Bodman MA. Point-of-care diagnosis of onychomycosis by dermoscopy. J Am Podiatr Med Assoc 2017; 107(5): 413-8.
[http://dx.doi.org/10.7547/16-183] [PMID: 29077504 ]
[73]
De Crignis G, Valgas N, Rezende P, Leverone A, Nakamura R. Dermatoscopy of onychomycosis. Int J Dermatol 2014; 53(2): e97-9.
[http://dx.doi.org/10.1111/ijd.12104] [PMID: 23786765 ]
[74]
Kaynak E, Göktay F, Güneş P, Sayman E, Turan D, Baygül A, et al. The role of dermoscopy in the diagnosis of distal lateral subungual onychomycosis. Arch Dermatol Res 2018; 310(1): 57-69.
[http://dx.doi.org/10.1007/s00403-017-1796-2] [PMID: 29177757]
[75]
Nargis T, Pinto M, Shenoy MM, Hegde S. Dermoscopic features of distal lateral subungual onychomycosis. Indian Dermatol Online J 2018; 9(1): 16-9.
[PMID: 29441292]
[76]
Gupta AK, Simpson FC. Diagnosing onychomycosis. Clin Dermatol 2013; 31(5): 540-3.
[http://dx.doi.org/10.1016/j.clindermatol.2013.06.009] [PMID: 24079582 ]
[77]
Bertanha L, Chiacchio ND. Nail clipping in onychomycosis. An Bras Dermatol 2016; 91(5): 688-90.
[http://dx.doi.org/10.1590/abd1806-4841.20164968] [PMID: 27828655]
[78]
Ghannoum M, Mukherjee P, Isham N, Markinson B, Rosso JD, Leal L. Examining the importance of laboratory and diagnostic testing when treating and diagnosing onychomycosis. Int J Dermatol 2018; 57(2): 131-8.
[http://dx.doi.org/10.1111/ijd.13690] [PMID: 28653769]
[79]
Bet DL, Reis AL, Di Chiacchio N, Belda W Junior. Dermoscopy and onychomycosis: Guided nail abrasion for mycological samples. An Bras Dermatol 2015; 90(6): 904-6.
[http://dx.doi.org/10.1590/abd1806-4841.20154615] [PMID: 26734877 ]
[80]
Karaman BFO, Açıkalın A, Ünal İ, Aksungur VL. Diagnostic values of KOH examination, histological examination, and culture for onychomycosis: A latent class analysis. Int J Dermatol 2019; 58(3): 319-24.
[http://dx.doi.org/10.1111/ijd.14255] [PMID: 30246397 ]
[81]
Gupta AK, Versteeg SG, Shear NH. Onychomycosis in the 21st century: An update on diagnosis, epidemiology, and treatment. J Cutan Med Surg 2017; 21(6): 525-39.
[http://dx.doi.org/10.1177/1203475417716362] [PMID: 28639462 ]
[82]
Watanabe S, Ishida K. Molecular diagnostic techniques for onychomycosis: Validity and potential application. Am J Clin Dermatol 2017; 18(2): 281-6.
[http://dx.doi.org/10.1007/s40257-016-0248-7] [PMID: 28160226 ]
[83]
Kandi V. Tungiasis presenting as onychomycosis: Probably the first report of flea infestation of the nail observed using modified potassium hydroxide mount technique. Cureus 2018; 10(3) e2278
[http://dx.doi.org/10.7759/cureus.2278] [PMID: 29736361 ]
[84]
Leung AK, Robson WL. Hair loss in children. J R Soc Health 1993; 113(5): 252-6.
[http://dx.doi.org/10.1177/146642409311300509] [PMID: 8230078 ]
[85]
Leung AK, Lam JM, Leong KF, Sergi CM. Melanonychia striata: Clarifying behind the black curtain. A review of clinical evaluation and management of the 21st century. Int J Dermatol 2019; 58(11): 1239-45.
[http://dx.doi.org/10.1111/ijd.14464] [PMID: 31006857 ]
[86]
Oztürk Durmaz E, Sezer E, Dikicioğlu Çetin E, Sahin S. Onychomatricoma masquerading as candidal onychomycosis and paronychia. Acta Dermatovenerol Croat 2013; 21(3): 198-201.
[PMID: 24183226]
[87]
Riahi RR, Cohen PR, Goldberg LH. Subungual amelanotic melanoma masquerading as onychomycosis. Cureus 2018; 10(3) e2307
[PMID: 29755903]
[88]
Goldstein AO, Bhatia N. Onychomycosis: Management. In: Post TW, ed UpToDate. Waltham, MA. (Accessed on June 30, 2019).
[89]
Ocampo-Garza J, Di Chiacchio NG, Di Chiacchio N, Machado-Filho CD. Acute transverse overcurvature of the nail due to onychomycosis. J Eur Acad Dermatol Venereol 2017; 31(4): e202-3.
[http://dx.doi.org/10.1111/jdv.13955] [PMID: 27579670 ]
[90]
Chacon A, Franca K, Fernandez A, Nouri K. Psychosocial impact of onychomycosis: A review. Int J Dermatol 2013; 52(11): 1300-7.
[http://dx.doi.org/10.1111/ijd.12122] [PMID: 24164152 ]
[91]
Gupta AK, Mays RR. The impact of onychomycosis on quality of life: A systematic review of the available literature. Skin Appendage Disord 2018; 4(4): 208-16.
[http://dx.doi.org/10.1159/000485632] [PMID: 30410887]
[92]
Milobratović D, Janković S, Vukičević J, Marinković J, Janković J, Railić Z. Quality of life in patients with toenail onychomycosis. Mycoses 2013; 56(5): 543-51.
[http://dx.doi.org/10.1111/myc.12072] [PMID: 23496237 ]
[93]
Gupta AK, Stec N. Recent advances in therapies for onychomycosis and its management. F1000Res 2019; 8 pii: F1000 Faculty Rev-968.
[http://dx.doi.org/10.12688/f1000research.18646.1]
[94]
Hanna S, Andriessen A, Beecker J, Gilbert M, Goldstein E, Kalia S, et al. Clinical insights about onychomycosis and its treatment: A consensus. J Drugs Dermatol 2018; 17(3): 253-62.
[PMID: 29537443]
[95]
Lipner SR. Pharmacotherapy for onychomycosis: New and emerging treatments. Expert Opin Pharmacother 2019; 20(6): 725-35.
[http://dx.doi.org/10.1080/14656566.2019.1571039] [PMID: 30689469 ]
[96]
Koshnick RL, Lilly KK, St Clair K, Finnegan MT, Warshaw EM. Use of diagnostic tests by dermatologists, podiatrists and family practitioners in the United States: Pilot data from a cross-sectional survey. Mycoses 2007; 50(6): 463-9.
[http://dx.doi.org/10.1111/j.1439-0507.2007.01422.x] [PMID: 17944707]
[97]
Gupta AK, Paquet M. Systemic antifungals to treat onychomycosis in children: A systematic review. Pediatr Dermatol 2013; 30(3): 294-302.
[http://dx.doi.org/10.1111/pde.12048] [PMID: 23278514 ]
[98]
Gupta AK, Mays RR, Versteeg SG, Shear NH, Friedlander SF. Onychomycosis in children: Safety and efficacy of antifungal agents. Pediatr Dermatol 2018; 35(5): 552-9.
[http://dx.doi.org/10.1111/pde.13561] [PMID: 29943838 ]
[99]
Kreijkamp-Kaspers S, Hawke K, Guo L, Kerin G, Bell-Syer SE, Magin P, et al. Oral antifungal medication for toenail onychomycosis. Cochrane Database Syst Rev 2017; 7 CD010031
[PMID: 28707751]
[100]
Ameen M, Lear JT, Madan V, Mohd Mustapa MF, Richardson M. British Association of Dermatologists’ guidelines for the management of onychomycosis 2014. Br J Dermatol 2014; 171(5): 937-58.
[http://dx.doi.org/10.1111/bjd.13358] [PMID: 25409999 ]
[101]
de Sá DC, Lamas AP, Tosti A. Oral therapy for onychomycosis: An evidence-based review. Am J Clin Dermatol 2014; 15(1): 17-36.
[http://dx.doi.org/10.1007/s40257-013-0056-2] [PMID: 24352873 ]
[102]
Yadav P, Singal A, Pandhi D, Das S. Comparative efficacy of continuous and pulse dose terbinafine regimes in toenail dermatophytosis: A randomized double-blind trial. Indian J Dermatol Venereol Leprol 2015; 81(4): 363-9.
[http://dx.doi.org/10.4103/0378-6323.158634] [PMID: 26087080 ]
[103]
Faergemann J, Anderson C, Hersle K, Hradil E, Nordin P, Kaaman T, et al. Double-blind, parallel-group comparison of terbinafine and griseofulvin in the treatment of toenail onychomycosis. J Am Acad Dermatol 1995; 32(5 Pt 1): 750-3.
[http://dx.doi.org/10.1016/0190-9622(95)91454-4] [PMID: 7722020 ]
[104]
Gupta AK, Foley KA, Mays RR, Shear NH, Piguet V. Monotherapy for toenail onychomycosis: A systematic review and network meta-analysis. Br J Dermatol 2019.
[http://dx.doi.org/10.1111/bjd.18155] [PMID: 31120134 ]
[105]
Dhamoon RK, Popli H, Gupta M. Novel drug delivery strategies for the treatment of onychomycosis. Pharm Nanotechnol 2019; 7(1): 24-38.
[http://dx.doi.org/10.2174/2211738507666190228104031] [PMID: 31092174]
[106]
Piraccini BM, Tosti A. Ciclopirox hydroxypropyl chitosan: Efficacy in mild-to-moderate onychomycosis. Skin Appendage Disord 2018; 5(1): 13-9.
[http://dx.doi.org/10.1159/000488606] [PMID: 30643775]
[107]
Canavan TN, Bevans SL, Cantrell WC, Wang C, Elewski BE. Single-center, prospective, blinded study comparing the efficacy and compatibility of efinaconazole 10% solution in treating onychomycosis with and without concurrent nail polish use. Skin Appendage Disord 2018; 5(1): 9-12.
[http://dx.doi.org/10.1159/000488369] [PMID: 30643774 ]
[108]
Zeichner JA, Stein Gold L, Korotzer A. Penetration of ((14)C)-efinaconazole topical solution, 10%, does not appear to be influenced by nail polish. J Clin Aesthet Dermatol 2014; 7(9): 34-6.
[PMID: 25276275]
[109]
Aly R, Gupta AK, Winter T, Zane LT, Vlahovic T. Tavaborole in difficult-to-treat onychomycosis cases: A post-hoc assessment of Phase III subjects. J Drugs Dermatol 2017; 16(10): 1016-21.
[PMID: 29036255]
[110]
Gupta AK, Hall S, Zane LT, Lipner SR, Rich P. Evaluation of the efficacy and safety of tavaborole topical solution, 5%, in the treatment of onychomycosis of the toenail in adults: A pooled analysis of an 8-week, post-study follow-up from two randomized Phase 3 studies. J Dermatolog Treat 2018; 29(1): 44-8.
[http://dx.doi.org/10.1080/09546634.2017.1329510] [PMID: 28521541 ]
[111]
Krasaeath R, Elizondo J. Topical antifungals for treatment of onychomycosis. Am Fam Physician 2016; 94(9): 734.
[PMID: 27929250]
[112]
Rich P, Spellman M, Purohit V, Zang C, Crook TJ. Tavaborole 5% topical solution for the treatment of toenail onychomycosis in pediatric patients: Results from a Phase 4 open-label study. J Drugs Dermatol 2019; 18(2): 190-5.
[PMID: 30811142]
[113]
Feng X, Xiong X, Ran Y. Efficacy and tolerability of amorolfine 5% nail lacquer in combination with systemic antifungal agents for onychomycosis: A meta-analysis and systematic review. Dermatol Ther 2017; 30(3)
[http://dx.doi.org/10.1111/dth.12457] [PMID: 28097731 ]
[114]
Eichenfield LF, Friedlander SF. Pediatric onychomycosis: The emerging role of topical therapy. J Drugs Dermatol 2017; 16(2): 105-9.
[PMID: 28300851]
[115]
Feldstein S, Totri C, Friedlander SF. Antifungal therapy for onychomycosis in children. Clin Dermatol 2015; 33(3): 333-9.
[http://dx.doi.org/10.1016/j.clindermatol.2014.12.010] [PMID: 25889135]
[116]
Ibrahim SA, Albalat W, Ebrahim HM. Evaluation of long pulsed Nd-YAG laser in the treatment of onychomycosis. J Cosmet Laser Ther 2019; 21(2): 76-81.
[http://dx.doi.org/10.1080/14764172.2018.1469765] [PMID: 29768066 ]
[117]
Gupta AK, Foley KA, Versteeg SG. Lasers for onychomycosis. J Cutan Med Surg 2017; 21(2): 114-6.
[http://dx.doi.org/10.1177/1203475416677722] [PMID: 27815496 ]
[118]
Abd El-Aal EB, Abdo HM, Ibrahim SM, Eldestawy MT. Fractional carbon dioxide laser assisted delivery of topical tazarotene versus topical tioconazole in the treatment of onychomycosis. J Dermatolog Treat 2019; 30(3): 277-82.
[http://dx.doi.org/10.1080/09546634.2018.1509046] [PMID: 30081698 ]
[119]
Bonhert K, Dorizas A, Sadick NS. Efficacy of combination therapy with efinaconazole 10% solution and 1064 nm Nd: YAG laser for treatment of toenail onychomycosis. J Cosmet Laser Ther 2019; 21(3): 179-83.
[http://dx.doi.org/10.1080/14764172.2018.1502451] [PMID: 30052090 ]
[120]
do Espírito Santo RB, Deps PD. Case study of onychomycosis patients treated with 1,064-nm Nd: YAG laser. Case Rep Dermatol 2018; 10(2): 216-25.
[http://dx.doi.org/10.1159/000492526] [PMID: 30283314 ]
[121]
Francuzik W, Fritz K, Salavastru C. Laser therapies for onychomycosis - Critical evaluation of methods and effectiveness. J Eur Acad Dermatol Venereol 2016; 30(6): 936-42.
[http://dx.doi.org/10.1111/jdv.13593] [PMID: 26953542 ]
[122]
Khater MH, Khattab FM. Combined long pulsed Nd-Yag laser and itraconazole versus itraconazole alone in the treatment of onychomycosis nails. J Dermatolog Treat 2019; 3: 1-19.
[http://dx.doi.org/10.1080/09546634.2019.1623861] [PMID: 31157575 ]
[123]
Okan G, Tarikci N, Gokdemir G. The effect of long-pulsed Nd: YAG laser for the treatment of onychomycosis. J Am Podiatr Med Assoc 2017; 107(1): 54-9.
[http://dx.doi.org/10.7547/15-137] [PMID: 28271946 ]
[124]
Piccolo D, Kostaki D, Del Duca E, Cannarozzo G, Sannino M, Nisticò S. Long-pulsed 1064-nm Nd: YAG laser for the treatment of onychomycosis. Photomed Laser Surg 2017; 35(4): 213-6.
[http://dx.doi.org/10.1089/pho.2016.4153] [PMID: 28061322 ]
[125]
Rivers JK, Vestvik BJ, Berkowitz J. Real-world efficacy of 1064-nm Nd: YAG laser for the treatment of onychomycosis. J Cutan Med Surg 2017; 21(2): 108-13.
[http://dx.doi.org/10.1177/1203475416676804] [PMID: 27856773 ]
[126]
Weber GC, Firouzi P, Baran AM, Bölke E, Schrumpf H, Buhren BA, et al. Treatment of onychomycosis using a 1064-nm diode laser with or without topical antifungal therapy: A single-center, retrospective analysis in 56 patients. Eur J Med Res 2018; 23(1): 53.
[http://dx.doi.org/10.1186/s40001-018-0340-y] [PMID: 30355363 ]
[127]
Wiznia LE, Quatrano NA, Mu EW, Rieder EA. A clinical review of laser and light therapy for nail psoriasis and onychomycosis. Dermatol Surg 2017; 43(2): 161-72.
[http://dx.doi.org/10.1097/DSS.0000000000000841] [PMID: 27465251 ]
[128]
Zawar V, Sarda A, De A. Clearance of recalcitrant onychomycosis following Q-switched Nd-Yag laser. J Cutan Aesthet Surg 2017; 10(4): 226-7.
[http://dx.doi.org/10.4103/JCAS.JCAS_18_17] [PMID: 29491660 ]
[129]
Zhou BR, Lu Y, Permatasari F, Huang H, Li J, Liu J, et al. The efficacy of fractional carbon dioxide (CO2) laser combined with luliconazole 1% cream for the treatment of onychomycosis: A randomized, controlled trial. Medicine (Baltimore) 2016; 95(44) e5141
[http://dx.doi.org/10.1097/MD.0000000000005141] [PMID: 27858846 ]
[130]
Gupta AK, Versteeg SG. A critical review of improvement rates for laser therapy used to treat toenail onychomycosis. J Eur Acad Dermatol Venereol 2017; 31(7): 1111-8.
[http://dx.doi.org/10.1111/jdv.14212] [PMID: 28294418]
[131]
El-Tatawy RA, Aliweh HA, Hegab DS, Talaat RAZ, Shams Eldeen MA. Fractional carbon dioxide laser and topical tioconazole in the treatment of fingernail onychomycosis. Lasers Med Sci 2019; 34(9): 1873-80.
[http://dx.doi.org/10.1007/s10103-019-02789-2] [PMID: 31025207 ]
[132]
Morgado LF, Trávolo ARF, Muehlmann LA, Narcizo PS, Nunes RB, Pereira PAG, et al. Photodynamic therapy treatment of onychomycosis with aluminium-phthalocyanine chloride nanoemulsions: A proof of concept clinical trial. J Photochem Photobiol B 2017; 173: 266-70.
[http://dx.doi.org/10.1016/j.jphotobiol.2017.06.010] [PMID: 28622558 ]
[133]
Alberdi E, Gómez C. Efficiency of methylene blue-mediated photodynamic therapy vs. intense pulsed light in the treatment of onychomycosis in the toenails. Photodermatol Photoimmunol Photomed 2019; 35(2): 69-77.
[http://dx.doi.org/10.1111/phpp.12420] [PMID: 30168611 ]
[134]
Bhatta AK, Keyal U, Wang XL. Photodynamic therapy for onychomycosis: A systematic review. Photodiagn Photodyn Ther 2016; 15: 228-35.
[http://dx.doi.org/10.1016/j.pdpdt.2016.07.010] [PMID: 27477248 ]
[135]
Bristow I, Baran R, Score M. Rapid treatment of subungual onychomycosis using controlled micro nail penetration and terbinafine solution. J Drugs Dermatol 2016; 15(8): 974-8.
[PMID: 27537998]
[136]
Chiu WS, Belsey NA, Garrett NL, Moger J, Price GJ, Delgado-Charro MB, et al. Drug delivery into microneedle-porated nails from nanoparticle reservoirs. J Control Release 2015. 220(Pt A):98-106.
[137]
Nam TS. Pharmaceutical composition for preventing or treating onychomycosis and preparation method therefor. WO2017018625 (2017).
[138]
Dars S, Banwell HA, Matricciani L. The use of urea for the treatment of onychomycosis: A systematic review. J Foot Ankle Res 2019; 12: 22.
[http://dx.doi.org/10.1186/s13047-019-0332-3] [PMID: 31007722]
[139]
Shemer A, Gupta AK, Babaev M, Barzilai A, Farhi R, Daniel Iii CR. A retrospective study comparing K101 nail solution as a monotherapy and in combination with oral terbinafine or itraconazole for the treatment of toenail onychomycosis. Skin Appendage Disord 2018; 4(3): 166-70.
[http://dx.doi.org/10.1159/000484211] [PMID: 30197895]
[140]
Repka MA, Mididoddi PK, Stodghill SP. Influence of human nail etching for the assessment of topical onychomycosis therapies. Int J Pharm 2004; 282(1-2): 95-106.
[http://dx.doi.org/10.1016/j.ijpharm.2004.06.010] [PMID: 15336385]
[141]
Amichai B, Nitzan B, Mosckovitz R, Shemer A. Iontophoretic delivery of terbinafine in onychomycosis: A preliminary study. Br J Dermatol 2010; 162(1): 46-50.
[http://dx.doi.org/10.1111/j.1365-2133.2009.09414.x] [PMID: 19785609]
[142]
Kushwaha A, Shivakumar HN, Murthy SN. Iontophoresis for drug delivery into the nail apparatus: Exploring hyponychium as the site of delivery. Drug Dev Ind Pharm 2016; 42(10): 1678-82.
[http://dx.doi.org/10.3109/03639045.2016.1165690] [PMID: 26981643 ]
[143]
Lipner SR, Scher RK. Management of onychomycosis and co-existing tinea pedis. J Drugs Dermatol 2015; 14(5): 492-4.
[PMID: 25942668]
[144]
Scher RK, Tosti A, Joseph WS, Vlahovic TC, Plasencia J, Markinson BC, et al. Onychomycosis diagnosis and management: Perspectives from a joint dermatology-podiatry roundtable. J Drugs Dermatol 2015; 14(9): 1016-21.
[PMID: 26355622]
[145]
Shemer A, Gupta AK, Kamshov A, Babaev M, Farhi R, Daniel CR, et al. Topical antifungal treatment prevents recurrence of toenail onychomycosis following cure Dermatol Ther 2017. 30(5).
[http://dx.doi.org/10.1111/dth.12545] [PMID: 28856784]
[146]
Tosti A, Elewski BE. Onychomycosis: Practical approaches to minimize relapse and recurrence. Skin Appendage Disord 2016; 2(1-2): 83-7.
[http://dx.doi.org/10.1159/000448056] [PMID: 27843933 ]
[147]
Kemna ME, Elewski BE A US. epidemiologic survey of superficial fungal diseases. J Am Acad Dermatol 1996; 35(4): 539-42.
[http://dx.doi.org/10.1016/S0190-9622(96)90675-1] [PMID: 8859279]
[148]
Al-Hatmi AM, Bonifaz A, Calderón L, Curfs-Breuker I, Meis JF, van Diepeningen AD, et al. Proximal subungual onychomycosis caused by Fusarium falciforme successfully cured with posaconazole. Br J Dermatol 2015; 173(1): 253-5.
[http://dx.doi.org/10.1111/bjd.13589] [PMID: 25565118 ]
[149]
Elewski B, Pollak R, Ashton S, Rich P, Schlessinger J, Tavakkol A. A randomized, placebo- and active-controlled, parallel-group, multicentre, investigator-blinded study of four treatment regimens of posaconazole in adults with toenail onychomycosis. Br J Dermatol 2012; 166(2): 389-98.
[http://dx.doi.org/10.1111/j.1365-2133.2011.10660.x] [PMID: 21967490 ]
[150]
Garvey EP, Hoekstra WJ, Moore WR, Schotzinger RJ, Long L, Ghannoum MA. VT-1161 dosed once daily or once weekly exhibits potent efficacy in treatment of dermatophytosis in a guinea pig model. Antimicrob Agents Chemother 2015; 59(4): 1992-7.
[http://dx.doi.org/10.1128/AAC.04902-14] [PMID: 25605358 ]
[151]
Sigurgeirsson B, van Rossem K, Malahias S, Raterink K. A phase II, randomized, double-blind, placebo-controlled, parallel group, dose-ranging study to investigate the efficacy and safety of 4 dose regimens of oral albaconazole in patients with distal subungual onychomycosis. J Am Acad Dermatol 2013; 69(3): 416-25.
[http://dx.doi.org/10.1016/j.jaad.2013.03.021] [PMID: 23706639]
[152]
Watanabe S, Tsubouchi I, Okubo A. Efficacy and safety of fosravuconazole L-lysine ethanolate, a novel oral triazole antifungal agent, for the treatment of onychomycosis: A multicenter, double-blind, randomized Phase III study. J Dermatol 2018; 45(10): 1151-9.
[http://dx.doi.org/10.1111/1346-8138.14607] [PMID: 30156314 ]
[153]
Yamaguchi H. Potential of ravuconazole and its prodrugs as the new oral therapeutics for onychomycosis. Med Mycol J 2016; 57(4): E93-E110.
[http://dx.doi.org/10.3314/mmj.16-00006] [PMID: 27904057 ]
[154]
Mercer DK, Stewart CS, Miller L, Robertson J, Duncan VMS, O’Neil DA. Improved methods for assessing therapeutic potential of antifungal agents against dermatophytes and their application in the development of NP213, a novel onychomycosis therapy candidate. Antimicrob Agents Chemother 2019; 63(5): e2117-8.
[http://dx.doi.org/10.1128/AAC.02117-18] [PMID: 30858219 ]
[155]
Viant P. Antifungal preparations intended for topical treatment of onychomycosis. US20180185490 (2018).
[156]
Zderic V, Kline-Schoder A, Lee Z. Ultrasound-enhanced drug delivery for treatment of onychomycosis. US20180092840 (2018).
[157]
Mizutani M, Tanaka T, Ogino H, Akazawa M. Onychomycosis therapeutic agent. WO2018110693 (2018).
[158]
Lundahl S. Method of treating onychomycosis. US20160220674 (2016).
[159]
Lipner SR, Friedman G, Scher RK. Pilot study to evaluate a plasma device for the treatment of onychomycosis. Clin Exp Dermatol 2017; 42(3): 295-8.
[http://dx.doi.org/10.1111/ced.12973] [PMID: 28188648 ]
[160]
Heinlin J, Maisch T, Zimmermann JL, et al. Contact-free inactivation of Trichophyton rubrum and Microsporum canis by cold atmospheric plasma treatment. Future Microbiol 2013; 8(9): 1097-106.
[http://dx.doi.org/10.2217/fmb.13.86] [PMID: 24020738]
[161]
Roe JN, Grammer TC, Barrera-Barraza RI, Tridas E. Onychomycosis treatment system and method. US20170189349 (2017).& WO2018175327 (2018).
[162]
Fernandez AG, Leon MF. Method for preparing product based on leaves of the Sedum telephium plant for the treatment of nails infected with onychomycosis. US20190167744 (2019).
[163]
Sonthalia S, Jakhar D, Yadav P, Kaur I. Chemical peeling as an innovative treatment alternative to oral antifungals for onychomycosis in special circumstances. Skin Appendage Disord 2019; 5(3): 181-5.
[http://dx.doi.org/10.1159/000495152] [PMID: 31049344]
[164]
Veiga FF, Costa MI, Cótica ÉSK, Svidzinski TIE, Negri M. Propolis for the treatment of onychomycosis. Indian J Dermatol 2018; 63(6): 515-7.
[PMID: 30504984]
[165]
Veiga FF, Gadelha MC, da Silva MRT, Costa MI, Kischkel B, de Castro-Hoshino LV, et al. Propolis extract for onychomycosis topical treatment: From bench to clinic. Front Microbiol 2018; 9: 779.
[http://dx.doi.org/10.3389/fmicb.2018.00779] [PMID: 29922236 ]
[166]
Mailland F, Caserini M, Ceriani D. Method to treat onychomycosis by hydroxypropyl chitosan. US20160213705 (2016) & US20170056386 (2017).
[167]
Gupta AK, Daigle D, Carviel JL. The role of biofilms in onychomycosis. J Am Acad Dermatol 2016; 74(6): 1241-6.
[http://dx.doi.org/10.1016/j.jaad.2016.01.008] [PMID: 27012826 ]
[168]
Gupta AK, Carviel J, Shear NH. Antibiofilm treatment for onychomycosis and chronic fungal infections. Skin Appendage Disord 2018; 4(3): 136-40.
[http://dx.doi.org/10.1016/j.jaad.2016.01.008] [PMID: 27012826 ]
[169]
Carlson RP, Taffs R, Davison WM, Stewart PS. Anti-biofilm properties of chitosan-coated surfaces. J Biomater Sci Polym Ed 2008; 19(8): 1035-46.
[http://dx.doi.org/10.1163/156856208784909372] [PMID: 18644229 ]
[170]
Granger BL, Flenniken ML, Davis DA, Mitchell AP, Cutler JE. Yeast wall protein 1 of Candida albicans. Microbiology 2005; 151(Pt 5): 1631-44.
[http://dx.doi.org/10.1099/mic.0.27663-0] [PMID: 15870471 ]
[171]
Rajendran R, Williams C, Lappin DF, Millington O, Martins M, Ramage G. Extracellular DNA release acts as an antifungal resistance mechanism in mature Aspergillus fumigatus biofilms. Eukaryot Cell 2013; 12(3): 420-9.
[http://dx.doi.org/10.1128/EC.00287-12] [PMID: 23314962 ]
[172]
Flores FC, Rosso RS, Cruz L, Beck RC, Silva CB. An innovative polysaccharide nanobased nail formulation for improvement of onychomycosis treatment. Eur J Pharm Sci 2017; 100: 56-63.
[173]
Costa-Orlandi CB, Mordorski B, Baltazar LM, Mendes-Giannini MJS, Friedman JM, Nosanchuk JD, et al. Nitric oxide releasing nanoparticles as a strategy to improve current onychomycosis treatments. J Drugs Dermatol 2018; 17(7): 717-20.
[PMID: 30005092]
[174]
Krainbring VGA. Composition for treating onychomycosis.WO2019105793 (2019).
[http://dx.doi.org/10.1016/j.ejps.2016.12.043] [PMID: 28063967 ]

Rights & Permissions Print Cite
Article Metrics
94
11
1
3
© 2024 Bentham Science Publishers | Privacy Policy